This node covers the software rails that move health-care work from a patient visit, prescription, claim, lab order, trial protocol, or clinician message into a paid transaction, documented workflow, data product, or automated task. The stack includes provider revenue-cycle tools, patient intake and payment software, health savings account and benefit-account rails, medication-management automation, clinician workflow networks, life-sciences data platforms, and regulated drug-development workflow software. The current basket keeps WAY first because it has the most direct provider payment-rail exposure; VEEV, IQV, DOCS, PHR, and HQY follow because they connect aging-demand pressure to recurring software, data, account, or workflow economics with clearer source support than the smaller tails.
What the stack is: health IT and data rails are the software, payments, identity, analytics, and workflow systems that sit around electronic health records, payer systems, pharmacy systems, clinical networks, labs, and life-sciences customer workflows.
What it does: the stack turns visits, claims, authorizations, prescriptions, patient forms, health-account transactions, medication orders, clinical trial tasks, and life-sciences data requests into cleaner documentation, faster cash collection, lower manual work, and customer-facing software revenue.
Main operating pieces: claim submission, denial management, remittance and reconciliation, patient intake, insurance verification, patient payments, health savings accounts, payment cards, medication cabinets and pharmacy automation, clinician identity networks, clinical AI tools, life-sciences commercial data, trial software, and biosimulation workflows.
Where it sits: these tools sit in provider offices, hospital pharmacy workflows, payer and clearinghouse connections, employer benefit accounts, clinician desktops, pharma commercial and R&D teams, diagnostics-data platforms, and the integrations between them.
How the theme uses it: aging demand raises encounters, claims, prescriptions, tests, care transitions, benefit-account transactions, and clinical workloads; the node works only when software reduces labor, speeds collections, improves retention, or creates measurable data and workflow revenue.
Terms used later: revenue cycle means the provider process from registration through claim, denial, payment, and reconciliation; net revenue retention measures expansion and contraction among existing customers; Data and Applications means TEM's data, analytics, and AI-enabled product line; R&DS means IQVIA's Research & Development Solutions segment; latest-quarter revenue means the most recent reported quarterly total revenue, not annualized sales.
Report boundary: this node is a tactical report layer. It ranks the current value-chain basket, setup labels, confirmation triggers, invalidation levels, and chart provenance. Durable research, raw source registries, and company thesis maintenance stay in the linked knowledge pages. Price and volume context comes from read-only discovery daily_ohlc through 2026-06-12.
Current Setup
Workflow conversion gateThe node pays when lower administrative work becomes revenue, retention, margin, or cash.
Provider payments and patient intake are the most direct routes. Life-sciences data and clinician workflow names need proof that usage, AI tools, or data products become paid adoption instead of only product activity.
Positive proofWAY has the cleanest payment-rail evidence.
Q1 2026 revenue grew 22%, NRR was 111%, and adjusted EBITDA margin was 43%.
Primary constraintSeveral direct workflow rows still lack durable local lanes.
PHR, HQY, OMCL, TDOC, and WAY need filed security lanes before company-specific claims should be expanded.
Demand sourceVisits, claims, scripts, trials
Workflow railData, payment, AI, automation
Company economicsRevenue, NRR, margin, FCF
Next proofQ2/Q3 reports + lane refresh
Aging demand raises the number of covered lives, encounters, diagnoses, claims, prescriptions, tests, and care transitions. That creates value only where software reduces a measured cost or unlocks a measured revenue path. The strongest proof is lower claim touches, denial rate, DSO, prior-auth cycle time, documentation time, medication-administration labor, or clinical-development friction, followed by renewal, retention, margin, and operating cash flow.
WAY leads because it is the most direct public provider payment rail in this basket: Q1 2026 revenue grew 22%, NRR was 111%, adjusted EBITDA margin was 43%, and management guided 2026 revenue to $1.274B-$1.294B. PHR is promoted to core because intake, insurance verification, forms, and patient-payment conversion are inside the same workflow problem, although it still lacks a durable local security lane. VEEV, IQV, and DOCS keep high ranks because they have local lanes, recurring workflow or data economics, and evidence that customers are already paying for regulated life-sciences or clinician workflow. HQY and OMCL add payment-account and medication-workflow routes. TEM and CERT keep data-rail exposure but rank lower because their current proof is more reimbursement, funding, services, or cash-burn sensitive.
The weak point is proof quality. Several direct workflow names are market-data-only in the local knowledge system, so official filings and company releases must carry the evidence until security lanes are filed. AI features can sound compelling while leaving revenue, retention, labor savings, collections, or margins unchanged. Provider budget delays, payer/API integration delays, cyber downtime, reimbursement rules, customer concentration, debt cost, stock compensation, and cash burn can all absorb the benefit even when usage rises. Static setup thresholds are stale because local daily_ohlc has moved to 2026-06-12 while the old setup package used 2026-06-11.
Static setup labels and thresholds remain from the prior 2026-06-11 node package. Local discovery now has daily_ohlc through 2026-06-12, so refresh static setup levels before using them as current trading evidence. Fundamental claims route to the Health Care sector lane, linked security lanes, SEC companyfacts, and official company releases listed in the Source Trail.
Basket
The ranked basket is inherited from the existing node metadata and rechecked against parent routing, local knowledge, SEC companyfacts, and bounded earnings-calendar work. Ranking uses direct node economics and source-backed exposure first, then cash quality and technical timing. WAY and PHR rank high because the workflow fit is direct; VEEV, IQV, DOCS, TEM, and CERT retain weight from durable local lanes; HQY, OMCL, and TDOC remain source-limited operating tails.
WAYWaystar Holding
Provider payment software is the most direct public route to claim, denial, remittance, and collection workflow economics.
Market cap$4.10B
Next earningsJul 29, 2026 est.
Latest qtr revenue$313.9M
Role in stack
Waystar sells provider revenue-cycle and payment software for claims, prior authorization, denial recovery, patient payments, remittance, and reconciliation. Hospitals and physician groups pay when the platform reduces claim work or speeds cash collection.
Revenue mix
Q1 2026 revenue was split between subscription revenue of $172.2M and volume-based revenue of $139.5M. The company said it serves about 30,000 clients, more than 1M providers, and over 7.5B annual healthcare payment transactions.
Latest qtr revenue
Q1 2026 revenue was $313.9M for the quarter ended March 31, 2026, from Waystar's April 29, 2026 results release. No durable local WAY security lane exists yet, so official releases carry the row.
Regulated life-sciences software turns clinical, regulatory, quality, safety, and commercial work into subscription revenue.
Market cap$27.1B
Next earningsNot confirmed
Latest qtr revenue$882.9M
Role in stack
Veeva sells vertical cloud software, data, and workflow tools to pharma and biotech customers. The economic route is subscription growth in regulated R&D, quality, safety, CRM, data, and AI workflows, with CRM migration and AI monetization as the conversion gates.
Revenue mix
Q1 FY2027 revenue was $882.9M, including $730.2M of subscription revenue. R&D and Quality is the larger product area versus Commercial, which keeps the row tied to regulated workflow rather than only sales software.
Latest qtr revenue
Q1 FY2027 revenue was $882.9M for the quarter ended April 30, 2026, from the VEEV security lane's latest research source. Nasdaq/Zacks had no upcoming earnings date as of the 2026-06-13 check.
Scaled life-sciences data, analytics, and clinical-development services give the node a broad sponsor workflow route.
Market cap$29.8B
Next earningsJul 28, 2026 est.
Latest qtr revenue$4.151B
Role in stack
IQVIA sells clinical research services, health-care data, analytics, commercial workflow, and AI-enabled tools to pharma and biotech customers. The route is trial backlog conversion, commercial analytics demand, and data/AI workflow adoption that survives margin and leverage pressure.
Revenue mix
Q1 2026 revenue was about $4.151B, split between Commercial Solutions near $1.754B and R&D Solutions near $2.397B. R&DS backlog was about $34.2B, with book-to-bill and cancellations as the live demand checks.
Latest qtr revenue
Q1 2026 revenue was $4.151B for the quarter ended March 31, 2026, from the IQV security lane's latest Q1 2026 source set. Nasdaq/Zacks labels the July 28, 2026 earnings date as an estimate.
Verified clinician workflow and clinical AI usage can matter if engagement converts to enterprise revenue and retention.
Market cap$4.80B
Next earningsAug 6, 2026 est.
Latest qtr revenue$145.4M
Role in stack
Doximity sells a verified clinician network, marketing, hiring, workflow, telehealth, and clinical AI tools to pharma and health-system customers. The route is subscription customer retention, workflow provider usage, enterprise AI contracts, and margin-stable expansion.
Revenue mix
Doximity reports one operating segment, so Marketing, Hiring, Workflow, and AI revenue are not separately visible. FY2026 revenue was 94% subscription customer revenue, and NRR fell to 109%, making renewal quality the main mix check.
Latest qtr revenue
Q4 FY2026 revenue was $145.4M for the quarter ended March 31, 2026, from Doximity's May 13, 2026 results release. The $644.9M full-year figure is not used as the card metric.
PHRPhreesia
Patient intake, insurance verification, forms, and payments sit directly in front-office provider workflow.
Market cap$618M
Next earningsNot confirmed
Latest qtr revenue$130.9M
Role in stack
Phreesia provides patient intake, scheduling-adjacent forms, insurance verification, payments, engagement, and life-sciences activation inside provider workflows. The buyer is primarily ambulatory practices, health systems, hospitals, and life-sciences customers.
Revenue mix
Local durable research is missing, so the mix should stay conservative: SEC companyfacts and instrument metadata support the integrated software, payments, and engagement platform route, but retention, customer concentration, and payment-conversion detail need a filed lane.
Latest qtr revenue
Q1 FY2027 revenue was $130.935M for the quarter ended April 30, 2026, from SEC companyfacts for CIK 0001412408. Nasdaq/Zacks had no upcoming earnings date as of the 2026-06-13 check.
HQYHealthEquity
HSA and consumer-directed benefit rails add payment-account exposure, but the route is indirect to provider workflow.
Market cap$7.17B
Next earningsNot confirmed
Latest qtr revenue$354.6M
Role in stack
HealthEquity administers health savings accounts, flexible spending accounts, health reimbursement arrangements, COBRA, commuter benefits, payment cards, and investment services. The economics come from service fees, custodial revenue, payment activity, employer/health-plan channels, and member asset balances.
Revenue mix
The business is payment-account infrastructure rather than clinical workflow. Local durable research is missing, so account growth, asset balances, custodial spread, card activity, and debt/cash metrics need a future lane before stronger company claims are made.
Latest qtr revenue
Q1 FY2027 revenue was $354.641M for the quarter ended April 30, 2026, from SEC companyfacts for CIK 0001428336. Nasdaq/Zacks had no upcoming earnings date as of the 2026-06-13 check.
OMCLOmnicell
Medication-management automation is a direct labor and pharmacy-workflow route for hospitals and pharmacies.
Market cap$1.99B
Next earningsJul 30, 2026 est.
Latest qtr revenue$309.9M
Role in stack
Omnicell sells medication-management automation, pharmacy workflow, and business analytics software to healthcare providers. The route is fewer medication-administration touches, better inventory control, service attachment, and hospital or pharmacy automation budgets.
Revenue mix
No durable local OMCL security lane was found. SEC companyfacts support current revenue, and local instruments describe automation and analytics software, but product mix, order quality, backlog, service attach, and hospital capex sensitivity still need source work.
Latest qtr revenue
Q1 2026 revenue was $309.880M for the quarter ended March 31, 2026, from SEC companyfacts for CIK 0000926326. Nasdaq/Zacks labels the July 30, 2026 earnings date as an estimate.
Diagnostics-funded data and AI exposure is real, but cash conversion and reimbursement keep it below cleaner workflow names.
Market cap$8.95B
Next earningsNot confirmed
Latest qtr revenue$348.1M
Role in stack
Tempus combines diagnostics, de-identified data, analytics, trial matching, and AI-enabled precision-medicine workflows. The customer route is providers and biopharma customers, with economics tied to diagnostic volume, reimbursement, Data and Applications growth, and cash conversion.
Revenue mix
Q1 2026 revenue was diagnostics-heavy: Diagnostics generated $261.1M and Data and Applications generated $87.0M. Data and Applications is the software-like route, but Diagnostics reimbursement and operating cash flow still govern the setup.
Latest qtr revenue
Q1 2026 revenue was $348.116M for the quarter ended March 31, 2026, from the TEM security lane's official Q1 2026 source set. Nasdaq/Zacks had no upcoming earnings date as of the 2026-06-13 check.
Model-informed drug-development software fits the node, but services softness and the divestiture reset cap the rank.
Market cap$967M
Next earningsAug 5, 2026 est.
Latest qtr revenue$106.9M
Role in stack
Certara sells biosimulation, model-informed drug-development, Clinical Intelligence, and regulated scientific workflow software and services to biopharma, biotech, academic, government, and regulator customers.
Revenue mix
Q1 2026 revenue was $106.9M, including $49.7M of software revenue and $57.2M of services revenue. Services declined, bookings slipped, and the Regulatory and Medical Writing sale changed the continuing-company bridge.
Latest qtr revenue
Q1 2026 revenue was $106.9M for the quarter ended March 31, 2026, from the CERT security lane's official Q1 2026 source set. Nasdaq/Zacks labels the August 5, 2026 earnings date as an estimate.
TDOCTeladoc Health
Virtual care and digital mental-health workflow are adjacent to the node but weaker than payment, data, and regulated workflow rails.
Market cap$1.31B
Next earningsAug 4, 2026 est.
Latest qtr revenue$613.8M
Role in stack
Teladoc provides virtual-care access, integrated care, and digital mental-health workflow through employers, insurers, health systems, and direct-to-consumer channels. The route is access fees, visits, utilization, retention, and margin improvement.
Revenue mix
Local instruments describe Integrated Care as the larger route and BetterHelp as the consumer mental-health route, but no durable TDOC security lane was found. Treat the row as adjacent workflow exposure until source-backed segment detail is filed.
Latest qtr revenue
Q1 2026 revenue was $613.845M for the quarter ended March 31, 2026, from SEC companyfacts for CIK 0001477449. Nasdaq/Zacks labels the August 4, 2026 earnings date as an estimate.
Market caps use read-only discovery instruments.market_cap queried on 2026-06-13. Next-earnings dates use Nasdaq/Zacks API checks on 2026-06-13 and are labeled est. when Nasdaq says the date is algorithmic. VEEV, PHR, HQY, and TEM returned no credible upcoming date, so the cards use Not confirmed. Watch list: HCAT and EVH remain parent watch names; SOLV, CTEV, PRVA, OPRX, and CNDT stay off the core list until local lanes or stronger official-source work are filed.
What Confirms Or Weakens
AreaWhat confirmsWhat weakens or invalidatesWatch next
01Node thesisWorkflow becomes economics
What confirms
Software lowers claim touches, denial rate, days sales outstanding, documentation time, medication-workflow labor, trial friction, or patient-payment friction, then shows up in revenue, NRR, margin, or operating cash flow.
What weakens or invalidates
AI and workflow usage rises without disclosed customer savings, retention, collections, revenue, margin, or cash conversion.
Watch next
WAY NRR
DOCS NRR
PHR profitability
VEEV subscription growth
02Economics mechanismPayment and data rails
What confirms
WAY, PHR, and HQY report stronger transaction, account, payment, client, or asset metrics while margins and cash flow hold.
What weakens or invalidates
Provider budget delays, payer/API friction, claim-denial regulation, cyber downtime, debt cost, or lower retention absorbs the workflow benefit.
Watch next
WAY 2026 guide
PHR intake/payment conversion
HQY HSA assets
Payment activity
03Customer demandLife sciences and providers
What confirms
VEEV subscription growth, IQV backlog conversion, TEM Data and Applications growth, CERT software bookings, and DOCS workflow adoption improve with stable customer budgets.
What weakens or invalidates
Pharma, biotech, health-system, or provider customers delay projects, cut discretionary spend, cancel studies, or use AI tools without paid expansion.
Watch next
VEEV Q2 FY2027
IQV R&DS book-to-bill
TEM Data and Applications
CERT software bookings
04Funding and balance sheetCash quality
What confirms
Operating cash flow covers product investment, integrations, debt service, and buybacks without heavier stock compensation or dilution.
05Policy and operating constraintRules, budgets, execution
What confirms
Reimbursement, privacy, AI governance, payer integration, and hospital budget conditions allow deployments to proceed without raising denial, compliance, or implementation costs.
What weakens or invalidates
Prior-authorization rules, reimbursement pressure, privacy rules, payer API delays, cyber incidents, or hospital capex constraints slow adoption or cut margin.
Watch next
CMS/payer rules
Diagnostics reimbursement
Cyber incidents
Hospital capex
06Source conditionLane coverage
What confirms
Durable security lanes are filed for WAY, PHR, HQY, OMCL, TDOC, HCAT, EVH, SOLV, CTEV, PRVA, OPRX, or CNDT before stronger company claims are made.
What weakens or invalidates
Market-data-only or SEC-companyfacts-only names are treated like fully researched lanes, or official sources cannot support claimed workflow savings, margins, retention, or cash conversion.
Watch next
File missing lanes
Refresh official sources
Rerank after earnings
07Stale conditionRefresh trigger
What confirms
Discovery remains current through 2026-06-12 and no material earnings, cyber, reimbursement, acquisition, financing, guidance, or filing event arrives before refresh.
What weakens or invalidates
A new filing, earnings release, cyber incident, guidance change, reimbursement rule, or trading session changes the evidence base before the static setup levels are refreshed.
Next-earnings dates were checked on 2026-06-13 through Nasdaq/Zacks API endpoints for WAY, VEEV, IQV, DOCS, PHR, HQY, OMCL, TEM, CERT, and TDOC. Nasdaq states estimated dates are algorithmic and may change after company announcements, so the Basket labels them est..
Estimated next earnings from Nasdaq/Zacks: WAY Jul 29, 2026; IQV Jul 28, 2026; DOCS Aug 6, 2026; OMCL Jul 30, 2026; CERT Aug 5, 2026; TDOC Aug 4, 2026. VEEV, PHR, HQY, and TEM returned no upcoming date, so the Basket uses Not confirmed.
Latest-quarter revenue references: WAY Q1 2026 $313.9M from Waystar's results release; VEEV Q1 FY2027 $882.9M from the VEEV lane source set; IQV Q1 2026 $4.151B from the IQV lane source set; DOCS Q4 FY2026 $145.4M from the DOCS lane and release; PHR, HQY, OMCL, and TDOC from SEC companyfacts; TEM Q1 2026 $348.116M from the TEM lane source set; CERT Q1 2026 $106.9M from the CERT lane source set.
Discovery And Chart Provenance
The chart API reads daily_ohlc from the local discovery store and returns weekly packages using first open, maximum high, minimum low, final close, and summed volume.
Read-only DuckDB checks on 2026-06-13 found daily_ohlc coverage through 2026-06-12 for WAY, VEEV, IQV, DOCS, PHR, HQY, OMCL, TEM, CERT, and TDOC. WAY has 505 local daily rows and TEM has 500; the older listed peers have at least 1,248 rows.
Market caps use read-only discovery instruments.market_cap queried on 2026-06-13. Basket values round those local figures: WAY $4.10B, VEEV $27.1B, IQV $29.8B, DOCS $4.80B, PHR $618M, HQY $7.17B, OMCL $1.99B, TEM $8.95B, CERT $967M, and TDOC $1.31B.
The selected-security chart rail expects /api/securities/{ticker}/chart?frequency=weekly&window=3y&as_of=latest. Charts should use weekly bars from daily_ohlc, first open, weekly high, weekly low, final close, summed volume, three-year visible horizon, 20-week EMA, 100-week EMA when enough history exists, and a volume subgraph.
The static setup thresholds in this node remain from the older 2026-06-11 package while the live API/local data is newer through 2026-06-12. Treat static thresholds as stale until refreshed; this page keeps chart evidence in the selected-security rail and embeds no inline OHLC payload.
Subagent Tournament
Ten primary subagents ranked the basket through lenses including life-sciences data rails, provider workflow, revenue cycle, AI workflow, tails, source quality, technical setup, integration, buyer economics, and plain-language QA.
One merge/select subagent performed the tournament merge. After the late revenue-cycle primary returned, it refreshed the final ranking to WAY, VEEV, IQV, DOCS, PHR, HQY, OMCL, TEM, CERT, and TDOC.
Rejected core promotions: HCAT, EVH, SOLV, CTEV, PRVA, OPRX, and CNDT are useful watch or research candidates, but local lanes or official-source depth are not yet sufficient for core ranking in this parent node.
Known Gaps
No durable local security lanes were found for WAY, PHR, HQY, OMCL, TDOC, HCAT, EVH, SOLV, CTEV, PRVA, OPRX, or CNDT. Treat those as official-source or market-data-only rows until filed.
PHR is promoted to core because the revenue-cycle and provider-workflow lenses both supported it. That makes a Phreesia security lane a high-priority follow-up before the next ranking refresh.
Provider payment-integrity tails such as CTEV can be thematically direct but balance-sheet risk and weaker local evidence keep them out of the basket.